K-V Pharmaceutical Company

Type: Public
On the web: http://www.kvpharma.com
Employees: 1,145
Employee growth: 6.8%

Just a spoonful of K-V Pharmaceutical helps the medicine go down. The firm owns a portfolio of drug delivery technologies -- including the know-how to create controlled-release pills, bioadhesive creams, and quick dissolving tablets -- that its subsidiaries use to develop new drugs and generic versions of existing ones. Its generics unit, ETHEX, makes hard-to-copy generic drugs in a number of therapeutic categories, including cardiovascular disease, women's health, pain management, and respiratory disease. Ther-Rx handles K-V's branded drugs, with a focus on women's health, cardiovascular, and anemia therapies. Its products include prenatal vitamins, as well as prescription yeast infection treatment Gynazole.

Key numbers for fiscal year ending March, 2007:
Sales: $443.6M
One year growth: 20.7%
Net income: $58.1M
Income growth: 267.9%

Officers:
Chairman and CEO: Marc S. Hermelin
VP Industry Presence and Development: Michael S. Anderson
Investor Relations and Corporate Communications: Catherine Biffignani

Competitors:
Biovail
Mylan Labs
Teva Pharmaceuticals